Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of Mycobacterium vaccae for injection (Micoka) in people aged 15 years or older with latent Mycobacterium tuberculosis infection
CTR20223390Phase 4Active
- Sponsor
- Anhui Zhifei Longcom Biopharmaceutical
- Start
- Apr 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of mycobacterium vaccae in latent tuberculosis infection (LTBI), pulmonary tuberculosis (TB), sponsored by Anhui Zhifei Longcom Biopharmaceutical. Started Apr 2023; status: active.
02
Drugs
mycobacterium vaccae
03
Conditions
latent tuberculosis infection (LTBI)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on CTR20223390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223390.